PRE and	ROUTI	NE TESTING FOR MS DMTs	ALL MS patients visits Q3-6mo and prn unless otherwise noted ALL MS patients Vit D level (check Q6mo) to keep >50.
NAME	MRI	LABS	Other tests
Avonex	Pre &	CBC w/diff, CMP, TSH	Monitor for depression and injection site reactions
Betaseron	Q6m-	Pre, Q3mo x 1yr then Q3-6mo	
Rebif	Qyear		
Plegridy			
Copaxone	Pre &	CBC w/diff, CMP Qyr	Monitor for lipoatrophy at injection sites
Glatopa	Q year		
Aubaugio	Pre &	Pre: Quantiferon Gold TB, CBC w/diff, CMP,	BLACK BOX: Hepatotoxicity and Teratogenicity
7mg or 14mg	Q6m-	pregnancy	Monitor BP at each visit. Monitor for skin rash.
PO QD	year	Post: CBC w/diff, CMP q1mo x 6 mo.	Ensure reliable birth control (male and female).
	&prn	Then q3mo	ACCELERATED ELIMINATION: Cholestyramine 8g TID x 11days
			Check Leflunomide levels for confirmation (<0.02mcg/mL).
Gilenya	Pre &	Pre: CBC w/diff, CMP, JCV w/ index	EKG: Pre, 6hr post 1 st dose, & Q1mo then Q6-12mo
0.5mg PO QD	Q6m-	Varicella titer	Optho: pre and q3-4 mo x 1yr then annually (r/o macular edema)
	year	Post: CBC w/diff, CMP Q3mo- annual JCV	Derm: pre (w/in 3mo of start) and annually for melanoma
	& prn	testing	Saftey Alert: Risk of increased disability with stopping Gilenya
Tecfidera	Pre &	Pre: CBC w/diff, CMP, JCV w/ index	Initial TECFIDERA titration: Take w/ meals - including healthy fat and protein
240mg PO BID	Q6m-	Post: CBC w/diff, CMP Q3mo – annual JCV	Week 1: take 120mg tab with dinner
(see titration)	year	testing	Week 2: take 240mg tab with dinner Week 3: take 120mg tab with breakfast and 240mg with dinner
Vumerity	& prn	Consider switching therapy if:	Week 4: take 240mg with breakfast and dinner.
231mg PO BID		JCV+ and Abs Lymph < 0.7 x10 ⁸ /L x 2 lab draws or if JCV- and Abs Lymph <0.5 x10 ⁸ /L x 2 lab draws	Vumerity: recommended to not take with high calorie meals (>700kcal) or ETOH
		* *	reduces peak plasma concentrations – but not overall absorption.
Tysabri	Pre &	Pre: CBC w/diff, CMP, JCV w/ index	Derm: pre and annually for melanoma
300mg IV	Q6m-		Black Box: PML risk with JCV+
Q4weeks	year	Post: CBC w/diff, CMP, JCV testing Q3mo	If JCV+ and >12 infusions consider alternate dosing Q6-8 wks
	& prn		With Q3 month Brain MRI w/o gad (T2 Flair – Sag/Axial)
Ocrevus	Pre &	Pre: CBC w/diff, CMP, JCV w/ index,	Pre-medicate 30-60min prior to each infusion with:
Initial: 300mg	Q6m-	Pregnancy, Anti-CD20 panel, Quant Gold TB	methylprednisolone 100mg IV, Acetaminophen 1000mg PO, and
IV x2wks apart Maint: 600mg Q6m	year	Hep B (Core Ab, Surface Ab, Surface Ag),	Diphenhydramine 50mg PO or IV
	& prn	Hep C Ab, Immunoglobulin G,M & A,	
		HIV (if high risk)	Consider repeating labs for:
Rituximab			Immunoglobulin (G, M & A) annually
Initial: 1000mg		Post: CBC w/diff, CMP, Anti-CD20 panel Q3-	Hep B & C testing Q2yrs
Maint: 500mg		6mo.	Annual Mammogram
Q6m			

NAME Lemtrada	MRI Pre &	Pre <30 days prior to 1 st infusion: CBC w/	Other tests -Pre-meds: Methylprednisolone 1000mg prior, plus Acetaminophen
Initial: 12mg IV	Q6m-	diff, CMP UA with cell count, TSH, Quant	1000mg PO, and Diphenhydramine 50mg PO or IV. Observe for 2 hrs
daily x 5 days	year	Gold TB, T4 free, Hep B (Core Ab, Surface	after each infusion, longer if clinically indicated.
Repeat 12	& prn	Ab, Surface Ag), Hep C Ab, VZV, Pap for	(ECG prior to each treatment course)
months later 12mg x 3 days	•	HPV, baseline skin exam	-Antiviral prophylaxis beginning 1 week prior to first treatment and
- repeat x1			for at least 2mo after until CD4+ >200mm
more year if		1 st infusion day labs: CBC w/diff, CMP, TSH,	-Listeria infections have developed as early as 3 days post treatment
needed		Pregnancy test, UA	and up to 8 months after the last dose. Patients should avoid
			or adequately heat foods that may potentially carry this bacteria
		Post: CBC w/diff, creatinine, TSH, CD4, UA	(deli meat, dairy products made with unpasteurized milk, soft
		with cell count monthly x 48mo after;	cheeses, or undercooked meat, seafood, or poultry). Patients
			advised to make dietary changes 2 wks prior to treatment Annual screening: HPV with Pap (If HPV+ increased frequency of GYN)
			and HPV screening), tuberculosis screening; s/s of PML; skin exams.
			Black Box: Bone marrow suppression, Infusion reactions, Infections,
			Autoimmune conditions (thyroid 40%, ITP, hepatitis and Anti-GBM
			disease), Malignancy (thyroid, lymphoproliferative, melanoma),
			Stroke and arterial dissection, thyroid disorders, cholecystitis and
			pneumonitis
Mayzent	Pre &	Pre: CBC w/diff, CMP, JCV w/ index, VZV	Macular edema (most often w/in 4mo of initiation), initial dosing
Titration: PO Day 1: 0.25mg	Q6m-	titer (ensure vaccinated)	bradycardia, increased infections, elevated LFTs, HTN, VZV
Day 1: 0.25mg Day 2: 0.25mg	year	Post: CBC w/diff, CMP Q3mo- annual JCV	reactivation and convulsions
Day 3: 0.50mg	& prn	testing	*First dose observation (FDO) only with cardiac conditions *if missed >4 days restart titration or FDO
Day 4: 0.75mg Day 5: 1.25mg			**Contraindicated with CYP2C9*3/*3 genotype, 6mo with MI,
Maint: 2mg QD			angina, stroke, TIA, CHF, heart block or sick sinus syndrome (unless
3 4			functioning pacer), Beta-blocker use

Mavenclad	Pre &	Pre: CBC w/diff, CMP, HIV, Hep B (Core Ab,	AEs: lymphopenia, increased infections (VZV), Hematologic toxicity,
3.5mg/kg PO	Q6m-	Surface Ab, Surface Ag), Hep C Ab, Quant	Graft vs. Host with blood transfusion, Liver injury. Risk of PML.
dosing x 5 days	year	Gold TB, Pregnancy, VZV (if neg immunize	Black Box: Increased risk Malignancy and Teratogenicity **MALES
4 weeks apart – repeat in	& prn	4-6wks prior)	and FEMALES (need reliable birth control prior and 6mo after last
12mo		Post: CBC at 2 and 6 months after the start	dose)
		of each yearly course (if 2-month	Annual cancer screening as applies for age and medical history
		lymphocyte <200 cells/mm then monitor	Herpes prophylaxis with Lymphocytes <200.
		monthly until month 6], and periodically	
		during and after treatment)	